menu
    • menu

    Find Bortezomib manufacturers, exporters & distributors on PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    65

    API Suppliers

    API Suppliers

    27

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    6

    JDMF

    JDMFs Filed

    14

    EU WC

    EU WC

    10

    KDMF

    KDMF

    21

    NDC API

    NDC API

    0

    VMF

    NDC API

    41

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 1,143,477

    MARKET PLACE

    6

    API

    10

    FDF

    12INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    144

    FDF Dossiers

    FDF Dossiers

    31

    FDA Orange Book

    FDA (Orange Book)

    20

    Europe

    Europe

    12

    Canada

    Canada

    34

    Australia

    Australia

    15

    South Africa

    South Africa

    32

    Listed Dossiers

    Listed Dossiers

    64DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    8

    Others

    PATENTS & EXCLUSIVITIES

    11

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    4

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    148

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    7,664,156

    Annual Reports

    13,452

    Finished Drug Prices

    Listed Dossiers

    32 RELATED EXCIPIENT COMPANIES

    64EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 179324-69-7, Velcade, Ps-341, Ldp-341, Bortezomib (ps-341), Radiciol
    Molecular Formula
    C19H25BN4O4
    Molecular Weight
    384.2  g/mol
    InChI Key
    GXJABQQUPOEUTA-RDJZCZTQSA-N
    FDA UNII
    69G8BD63PP
    Bortezomib
    A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.
    Bortezomib is a Proteasome Inhibitor. The mechanism of action of bortezomib is as a Proteasome Inhibitor.
    1 2D Structure

    Bortezomib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
    2.1.2 InChI
    InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
    2.1.3 InChI Key
    GXJABQQUPOEUTA-RDJZCZTQSA-N
    2.1.4 Canonical SMILES
    B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
    2.1.5 Isomeric SMILES
    B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
    2.2 Other Identifiers
    2.2.1 UNII
    69G8BD63PP
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 341, Ps

    2. Ldp 341

    3. Ldp-341

    4. Ldp341

    5. Ps 341

    6. Ps-341

    7. Ps341

    8. Velcade

    2.3.2 Depositor-Supplied Synonyms

    1. 179324-69-7

    2. Velcade

    3. Ps-341

    4. Ldp-341

    5. Bortezomib (ps-341)

    6. Radiciol

    7. Ps 341

    8. ((r)-3-methyl-1-((s)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic Acid

    9. Dpba

    10. Ldp 341

    11. Bortezomib Accord

    12. Nsc-681239

    13. [(1r)-3-methyl-1-[[(2s)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic Acid

    14. Bortezomib (velcade)

    15. N-[(1r)-1-(dihydroxyboryl)-3-methylbutyl]-n-(pyrazin-2-ylcarbonyl)-l-phenylalaninamide

    16. Mln-341

    17. [(1r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid

    18. Mg 341

    19. Mg-341

    20. Boronic Acid, B-[(1r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-

    21. Nsc 681239

    22. 69g8bd63pp

    23. Chembl325041

    24. Peptide Boronate

    25. Chebi:52717

    26. Nsc681239

    27. Ncgc00242506-02

    28. S1013

    29. Dsstox_cid_20980

    30. Dsstox_rid_79609

    31. N-[(1r)-1-(dihydroxyboranyl)-3-methylbutyl]-nalpha-(pyrazin-2-ylcarbonyl)-l-phenylalaninamide

    32. Dsstox_gsid_40980

    33. Pyz-phe-boroleu

    34. (r)-3-methyl-1-((s)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic Acid

    35. ((1r)-3-methyl-1-(((2s)-3-phenyl-2-((pyrazinylcarbonyl)amino)propanoyl)amino)butyl)boronic Acid

    36. [(1r)-3-methyl-1-({(2s)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic Acid

    37. Boronic Acid, ((1r)-3-methyl-1-(((2s)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-

    38. N-((1s)-1-benzyl-2-(((1r)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide

    39. Velcade (tn)

    40. Cas-179324-69-7

    41. Ps 341 (pharmaceutical)

    42. Unii-69g8bd63pp

    43. Brotezamide

    44. Proscript Boronic Acid

    45. Bortezomib [usan:inn:ban]

    46. Hsdb 7666

    47. Bortezomib Hydrate

    48. Bortezomib,velcade

    49. Lpd 341

    50. Lpd-341

    51. Ncgc00168751-01

    52. Ncgc00181022-01

    53. Bortezomib- Bio-x

    54. Bortezomib [usan]

    55. Mfcd09056737

    56. Velcade (millenium)

    57. 3mg0

    58. Bortezomib [mi]

    59. Bortezomib [inn]

    60. Bortezomib [jan]

    61. Bortezomib [hsdb]

    62. Bortezomib [vandf]

    63. Bortezomib [mart.]

    64. Bortezomib [who-dd]

    65. Mls004774142

    66. Bortezomib (jan/usan/inn)

    67. Bortezomib [ema Epar]

    68. Schembl192129

    69. Gtpl6391

    70. Bortezomib [orange Book]

    71. Bortezomib Hydrate [jan]

    72. Dtxsid3040980

    73. Tox21_112630

    74. Tox21_112672

    75. Bdbm50069989

    76. Nsc756655

    77. Akos015909706

    78. Tox21_112672_1

    79. Zinc169746649

    80. Am81235

    81. Ccg-268449

    82. Cs-1039

    83. Db00188

    84. Nsc-756655

    85. Bortezomib (velcade,mg-341,ps-341)

    86. Ncgc00242506-01

    87. Ncgc00242506-06

    88. Ncgc00242506-07

    89. As-15721

    90. Bb164258

    91. Hy-10227

    92. Nci60_029010

    93. Smr003500787

    94. B5741

    95. Sw208077-3

    96. A18332

    97. D03150

    98. Ab01273951-01

    99. Ab01273951-02

    100. Ab01273951_03

    101. 324b697

    102. Q419319

    103. Sr-01000939863

    104. Sr-01000939863-2

    105. Brd-k88510285-001-02-0

    106. ((r)-3-methyl-1-((s)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronicacid

    107. (r)-3-methyl-1-((s)-3-phenyl-2-(pyrazine-6-carboxamido)propanamido)butylboronic Acid

    108. (1r)-3-methyl-1-({(2s)-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propanoyl}amino)butylboronic Acid, Aldrichcpr

    109. (r)-3-methyl-1-((s)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butan-2-ylboronic Acid

    110. [(1r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]-butyl]boronic Acid

    111. 1610526-91-4

    112. Boronic Acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (s-(r*,s*))-

    113. Boronic Acid, [(1(r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-

    114. N-((1s)-1-benzyl-2-(((1r)-1-(dihydroxyboranyl)-3-methylbutyl)amino)2-oxoethylpyrazinecarboxamide

    115. N-[(1r)-1-(dihydroxyboranyl)-3-methylbutyl]-n(alpha)-(pyrazin-2-ylcarbonyl)-l-phenylalaninamide

    2.4 Create Date
    2005-03-26
    3 Chemical and Physical Properties
    Molecular Weight 384.2 g/mol
    Molecular Formula C19H25BN4O4
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count9
    Exact Mass384.1968855 g/mol
    Monoisotopic Mass384.1968855 g/mol
    Topological Polar Surface Area124 Ų
    Heavy Atom Count28
    Formal Charge0
    Complexity500
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameVelcade
    PubMed HealthBortezomib (Injection)
    Drug ClassesAntineoplastic Agent
    Drug LabelVELCADE (bortezomib) for Injection is an antineoplastic agent available for intravenous injection or subcutaneous use. Each single use vial contains 3.5 mg of bortezomib as a sterile lyophilized powder. Inactive ingredient: 35 mg mannitol, USP.Bort...
    Active IngredientBortezomib
    Dosage FormInjectable
    RouteIntravenous, subcutaneous
    Strength3.5mg/vial
    Market StatusPrescription
    CompanyMillennium Pharms

    2 of 2  
    Drug NameVelcade
    PubMed HealthBortezomib (Injection)
    Drug ClassesAntineoplastic Agent
    Drug LabelVELCADE (bortezomib) for Injection is an antineoplastic agent available for intravenous injection or subcutaneous use. Each single use vial contains 3.5 mg of bortezomib as a sterile lyophilized powder. Inactive ingredient: 35 mg mannitol, USP.Bort...
    Active IngredientBortezomib
    Dosage FormInjectable
    RouteIntravenous, subcutaneous
    Strength3.5mg/vial
    Market StatusPrescription
    CompanyMillennium Pharms

    4.2 Therapeutic Uses

    Antineoplastic Agents; Protease Inhibitors

    National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)

    Bortezomib injection is indicated for the treatment of patients with multiple myeloma who have received at least 1 prior therapy. /Included in US product label/

    US Natl Inst Health; DailyMed. Current Medication Information for Velcade (Bortezomib) (January 2008). Available from, as of November 25, 2008: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6358

    Bortezomib injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy. /Included in US product label/

    US Natl Inst Health; DailyMed. Current Medication Information for Velcade (Bortezomib) (January 2008). Available from, as of November 25, 2008: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6358

    4.3 Drug Warning

    Known hypersensitivity to bortezomib, boron, or mannitol.

    American Society of Health System Pharmacists. AHFS Drug Information 2008. Bethesda, Maryland 2008, p. 929

    Bortezomib mainly causes sensory peripheral neuropathy, but severe motor peripheral neuropathy also has been reported. In the phase III trial, peripheral neuropathy occurred in 36% of patients receiving bortezomib and 9% of patients receiving dexamethasone. Grade 3 or 4 peripheral neuropathy occurred in 7 or less than 1%, respectively, of patients receiving bortezomib. Following dosage adjustments, amelioration or resolution of peripheral neuropathy was reported in 51% of patients with grade 2 or higher peripheral neuropathy within a median of 3.5 months from onset. About 8% of patients discontinued bortezomib therapy because of peripheral neuropathy.

    American Society of Health System Pharmacists. AHFS Drug Information 2008. Bethesda, Maryland 2008, p. 929

    Patients receiving bortezomib should be monitored for manifestations of neuropathy (eg, burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, neuropathic pain). Dose and/or frequency of administration of bortezomib should be adjusted in patients who experience new-onset or exacerbation of peripheral neuropathy.

    American Society of Health System Pharmacists. AHFS Drug Information 2008. Bethesda, Maryland 2008, p. 929

    In the phase III trial, asthenia (ie, fatigue, malaise, weakness) was reported in 61% of patients receiving bortezomib and 45% of patients receiving dexamethasone. Grade 3 asthenia occurred in 12 versus 6%, respectively, of patients receiving bortezomib or dexamethasone. About 3% of patients receiving bortezomib and 2% of patients receiving dexamethasone discontinued therapy because of asthenia.

    American Society of Health System Pharmacists. AHFS Drug Information 2008. Bethesda, Maryland 2008, p. 929

    For more Drug Warnings (Complete) data for BORTEZOMIB (26 total), please visit the HSDB record page.

    4.4 Drug Indication

    Bortezomib is indicated for the treatment of adult patients with multiple myeloma or mantle cell lymphoma.

    FDA Label

    Velcade as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.

    Velcade in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high dose chemotherapy with haematopoietic stem cell transplantation.

    Velcade in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high dose chemotherapy with haematopoietic stem cell transplantation.

    Velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

    Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.

    Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

    Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

    Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

    Bortezomib as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.

    Bortezomib in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

    Bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

    Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

    Bortezomib SUN as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.

    Bortezomib SUN in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

    Bortezomib SUN in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

    Bortezomib SUN in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

    Bortezomib Accord as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.

    Bortezomib Accord in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for highdose chemotherapy with haematopoietic stem cell transplantation.

    Bortezomib Accord in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for highdose chemotherapy with haematopoietic stem cell transplantation.

    Bortezomib Accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

    Treatment of mantle cell lymphoma

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Bortezomib works to target the ubiquitin-proteasome pathway, an essential molecular pathway that regulates intracellular concentrations of proteins and promotes protein degradation. The ubiquitin-proteasome pathway is often dysregulated in pathological conditions, leading to aberrant pathway signalling and the formation of malignant cells. In one study, patient-derived chronic lymphocytic leukemia (CLL) cells contained 3-fold higher levels of chymotrypsin-like proteasome activity than normal lymphocytes. By reversibly inhibiting proteasome, bortezomib prevents proteasome-mediated proteolysis. Bortezomib exerts a cytotoxic effect on various cancer cell types _in vitro_ and delays tumour growth _in vivo_ in nonclinical tumour models. Bortezomib inhibits the proteasome activity in a dose-dependent manner. In one pharmacodynamic study, more than 75% of proteasome inhibition was observed in whole blood samples within one hour after dosing of bortezomib.

    5.2 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    BORTEZOMIB
    5.3.2 FDA UNII
    69G8BD63PP
    5.3.3 Pharmacological Classes
    Proteasome Inhibitors [MoA]; Proteasome Inhibitor [EPC]
    5.4 ATC Code

    L01XG01

    L01XG01

    L01XG01

    L01XG01

    L01XX32

    L01XX32

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01X - Other antineoplastic agents

    L01XG - Proteasome inhibitors

    L01XG01 - Bortezomib

    5.5 Absorption, Distribution and Excretion

    Absorption

    Following intravenous administration of 1 mg/m2 and 1.3 mg/m2 doses, the mean Cmax of bortezomib were 57 and 112 ng/mL, respectively. In a twice-weekly dosing regimen, the Cmax ranged from 67 to 106 ng/mL at the dose of 1 mg/m2 and 89 to 120 ng/mL for the 1.3 mg/m2 dose. In patients with multiple myeloma, the Cmax of bortezomib followig subcutaneous administration was lower than that of intravenously-administered dose; however, the total systemic exposure of the drug was equivalent for both routes of administration. There is a wide interpatient variability in drug plasma concentrations.

    Route of Elimination

    Bortezomib is eliminated by both renal and hepatic routes.

    Volume of Distribution

    The mean distribution volume of bortezomib ranged from approximately 498 to 1884 L/m2 in patients with multiple myeloma receiving a single- or repeat-dose of 1 mg/m2 or 1.3 mg/m2. Bortezomib distributes into nearly all tissues, except for the adipose and brain tissue.

    Clearance

    Following the administration of a first dose of 1 mg/m2 and 1.3 mg/m2, the mean mean total body clearances were 102 and 112 L/h, respectively. The clearances were 15 and 32 L/h after the subsequent dose of 1 and 1.3 mg/m2, respectively.

    Following intravenous administration of 1 mg/sq m and 1.3 mg/sq m doses to 24 patients with multiple myeloma (n=12, per each dose level), the mean maximum plasma concentrations of bortezomib (Cmax) after the first dose (Day 1) were 57 and 112 ng/mL, respectively.

    US Natl Inst Health; DailyMed. Current Medication Information for Velcade (Bortezomib) (January 2008). Available from, as of November 25, 2008: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6358

    In subsequent doses, when administered twice weekly, the mean maximum observed plasma concentrations ranged from 67 to 106 ng/mL for the 1 mg/sq m dose and 89 to 120 ng/mL for the 1.3 mg/sq m dose. The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/sq m dose and 76 to 108 hours after the 1.3 mg/sq m dose. The mean total body clearances was 102 and 112 L/hr following the first dose for doses of 1 mg/sq m and 1.3 mg/sq m, respectively, and ranged from 15 to 32 L/hr following subsequent doses for doses of 1 and 1.3 mg/sq m, respectively.

    US Natl Inst Health; DailyMed. Current Medication Information for Velcade (Bortezomib) (January 2008). Available from, as of November 25, 2008: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6358

    The mean distribution volume of bortezomib ranged from approximately 498 to 1884 L/sq m following single- or repeat-dose administration of 1 mg/sq m or 1.3mg/sq m to patients with multiple myeloma. This suggests bortezomib distributes widely to peripheral tissues. The binding of bortezomib to human plasma proteins averaged 83% over the concentration range of 100 to 1000 ng/mL.

    US Natl Inst Health; DailyMed. Current Medication Information for Velcade (Bortezomib) (January 2008). Available from, as of November 25, 2008: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6358

    It is not known whether bortezomib is excreted in human milk.

    US Natl Inst Health; DailyMed. Current Medication Information for Velcade (Bortezomib) (January 2008). Available from, as of November 25, 2008: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6358

    For more Absorption, Distribution and Excretion (Complete) data for BORTEZOMIB (6 total), please visit the HSDB record page.

    5.6 Metabolism/Metabolites

    Bortezomib is primarily metabolized by CYP3A4, CYP2C19, and CYP1A2. CYP2D6 and CYP2C9 are also involved in drug metabolism, but to a smaller extent. Oxidative deboronation, which involves the removal of boronic acid from the parent compound, is the main metabolic pathway. Metabolites of bortezomib are pharmacologically inactive and more than 30 metabolites have been identified in human and animal studies.

    In vitro studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolized via cytochrome P450 enzymes 3A4, 2C19, and 1A2. Bortezomib metabolism by CYP 2D6 and 2C9 enzymes is minor. The major metabolic pathway is deboronation to form 2 deboronated metabolites that subsequently undergo hydroxylation to several metabolites. Deboronated bortezomib metabolites are inactive as 26S proteasome inhibitors. Pooled plasma data from 8 patients at 10 min and 30 min after dosing indicate that the plasma levels of metabolites are low compared to the parent drug.

    US Natl Inst Health; DailyMed. Current Medication Information for Velcade (Bortezomib) (January 2008). Available from, as of November 25, 2008: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6358

    ... The P450 inhibition potential of bortezomib and its major deboronated metabolites M1 and M2 and their dealkylated metabolites M3 and M4 was evaluated in human liver microsomes for the major P450 isoforms 1A2, 2C9, 2C19, 2D6, and 3A4/5. Bortezomib, M1, and M2 were found to be mild inhibitors of CYP2C19 (IC(50) approximately 18.0, 10.0, and 13.2 microM, respectively), and M1 was also a mild inhibitor of CYP2C9 (IC(50) approximately 11.5 microM). However, bortezomib, M1, M2, M3, and M4 did not inhibit other P450s (IC(50) values > 30 microM). There also was no time-dependent inhibition of CYP3A4/5 by bortezomib or its major metabolites. ...

    PMID:16443666 LU C et al; Drug Metab Dispos 34 (4): 702-8 (2006)

    ... Bortezomib binds the proteasome via the boronic acid moiety, and therefore, the presence of this moiety is necessary to achieve proteasome inhibition. Metabolites in plasma obtained from patients receiving a single intravenous dose of bortezomib were identified and characterized by liquid chromatography/mass spectrometry (LC/MS) and liquid chromatography/tandem mass spectrometry (LC/MS/MS). Metabolite standards that were synthesized and characterized by LC/MS/MS and high field nuclear magnetic resonance spectroscopy (NMR) were used to confirm metabolite structures. The principal biotransformation pathway observed was oxidative deboronation, most notably to a pair of diastereomeric carbinolamide metabolites. Further metabolism of the leucine and phenylalanine moieties produced tertiary hydroxylated metabolites and a metabolite hydroxylated at the benzylic position, respectively. Conversion of the carbinolamides to the corresponding amide and carboxylic acid was also observed. Human liver microsomes adequately modeled the in vivo metabolism of bortezomib, as the principal circulating metabolites were observed in vitro. Using cDNA-expressed cytochrome P450 isoenzymes, it was determined that several isoforms contributed to the metabolism of bortezomib, including CYP3A4, CYP2C19, CYP1A2, CYP2D6, and CYP2C9. ...

    PMID:15764713 Pekol T et al; Drug Metab Dispos 33 (6): 771-7 (2005)

    5.7 Biological Half-Life

    The mean elimination half-life of bortezomib ranged from 40 to 193 hours following a multiple dosing regimen at a 1 mg/m2 dose. The half-life ranged from 76 to 108 hours after multiple dosing of 1.3 mg/m2 bortezomib.

    The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/sq m dose and 76 to 108 hours after the 1.3 mg/sq m dose.

    US Natl Inst Health; DailyMed. Current Medication Information for Velcade (Bortezomib) (January 2008). Available from, as of November 25, 2008: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6358

    5.8 Mechanism of Action

    The ubiquitin-proteasome pathway is a homeostatic proteolytic pathway for intracellular protein degradation: proteins marked with a poly-ubiquitin chain are degraded to small peptides and free ubiquitin by the proteasome, which is a large multimeric protease. Aberrant proteasome-dependent proteolysis, as seen in some malignancies, can lead to uncontrolled cell division, leading to tumorigenesis, cancer growth, and spread. Bortezomib is a reversible inhibitor of the 26S proteasome, which is made up of a 20S core complexed with a 19S regulatory complex. Individual -subunits allow specific catalytic action of the 20S core. In mammalian cells, bortezomib is a potent inhibitor of the proteasomes chymotryptic-like activity, which is attributed to the 5-subunit of the 20S core particle. Bortezomib binds to the active site of the threonine hydroxyl group in the 5-subunit. A probing study showed bortezomib also binding to and inhibiting the 1-subunit, which mediates the caspase-like activity of the proteasome, and 1i-subunit, which is an altered subunit that is expressed to form immunoproteasomes in response to cell stress or inflammation. By inhibiting the proteasome-mediated degradation of key proteins that promote cell apoptosis, bortezomib induces a cell cycle arrest during the G2-M phase. It is believed that multiple mechanisms, other than proteasome inhibition, may be involved in the anticancer activity of bortezomib. The anticancer activity of bortezomib was largely associated with suppression of the NF-B signalling pathway, resulting in the downregulation of anti-apoptotic target genes and expression of anti-apoptic proteins. This may be explained by bortezomib preventing uncontrolled degradation of IB, which is an inhibitory protein of NF-B. NOXA, which is a pro-apoptotic factor, induced by bortezomib selectively in cancer cells; thus, it is suggested to be another key mechanism of bortezomib.

    Bortezomib, a modified dipeptidyl boronic acid, is an antineoplastic agent. The drug reversibly inhibits the 26S proteasome, a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome by bortezomib prevents targeted proteolysis and causes disruption of normal homeostatic mechanisms, which can lead to cell death. In vitro studies indicate that bortezomib is cytotoxic to a variety of cancer cell types. Bortezomib has been shown to cause a delay in tumor growth in vivo in tumor models, including multiple myeloma.

    American Society of Health System Pharmacists. AHFS Drug Information 2008. Bethesda, Maryland 2008, p. 931

    ... The mechanisms underlying /bortezomib/ cancer cell toxicity are complex. A growing body of evidence suggests proteasome inhibition-dependent regulation of the BCL-2 family is a critical requirement. In particular, the stabilization of BH3-only proteins BIK, NOXA and BIM, appear to be essential for effecting BAX- and BAK-dependent cell death. ...

    PMID:17828309 Fennell DA et al; Oncogene 27 (9): 1189-97 (2008)

    Proteasome inhibition is a novel, targeted approach in cancer therapy. Both natural and synthetic proteasome inhibitors selectively penetrate cancer cells, disrupting the orderly destruction of key regulatory proteins involved in tumorigenesis and metastasis. Disrupting the orderly destruction of regulatory proteins causes an imbalance of these proteins within the cell, which interferes with the systematic activation of signaling pathways required to maintain tumor cell growth and survival; therefore, cellular replication is inhibited and apoptosis ensues. ...

    PMID:15688597 Jung L et al; Oncology (Williston Park) 18 (14 Suppl 11): 4-13 (2004)

    Bortezomib (PS-341, Velcade) is a potent and selective inhibitor of the proteasome that is currently under investigation for the treatment of solid malignancies. /Investigators/ have shown previously that bortezomib has activity in pancreatic cancer models and that the drug induces endoplasmic reticulum (ER) stress but also suppresses the unfolded protein response (UPR). Because the UPR is an important cytoprotective mechanism, /investigators/ hypothesized that bortezomib would sensitize pancreatic cancer cells to ER stress-mediated apoptosis. Here, /the authors/ show that bortezomib promotes apoptosis triggered by classic ER stress inducers (tunicamycin and thapsigargin) via a c-Jun NH(2)-terminal kinase (JNK)-dependent mechanism. /They/ also show that cisplatin stimulates ER stress and interacts with bortezomib to increase ER dilation, intracellular Ca(2+) levels, and cell death. Importantly, combined therapy with bortezomib plus cisplatin induced JNK activation and apoptosis in orthotopic pancreatic tumors resulting in a reduction in tumor burden. Taken together, the data establish that bortezomib sensitizes pancreatic cancer cells to ER stress-induced apoptosis and show that bortezomib strongly enhances the anticancer activity of cisplatin.

    PMID:16357177 Nawrocki ST et al; Cancer Res 65 (24): 11658-66 (2005)

    API SUPPLIERS

    read-more
    read-more

    01

    Biophore India Pharmaceuticals Pvt...

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2015-12-04

    Pay. Date : 2015-09-09

    DMF Number : 29506

    Submission : 2015-08-27

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Biophore

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    LGM Pharma

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    DKSH

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

    Contact Supplier Contact Supplier
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    DKSH Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Dr. Reddy's Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2023-06-30

    Pay. Date : 2023-06-27

    DMF Number : 23996

    Submission : 2010-07-26

    Status : Active

    Type : II

     CEP/COS JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-06-06

    Valid Till : 2025-07-07

    Written Confirmation Number : WC-0039

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 55111-922

    Start Marketing Date : 2012-07-30

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Gonane Pharma

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothGonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Gonane Pharma

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    HRV Global Life Sciences

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPHI Middle east
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothHRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF AU, ASMF arrow-down
    ✖
    Available Reg Filing : AU, ASMF
    AUDIT
    HRV Global Life Sciences

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Tofigh Daru

    Iran

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTofigh Daru develops & synthesizes a diverse range of APIs in Anticancer, Narcotics, Cardiovascular to Immunomodulatory Segments.

    Contact Supplier Contact Supplier
    Flag Iran
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Tofigh Daru

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    TAPI Technology & API Services

    Israel

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Booth #6.1A32
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTAPI offers customized CDMO Solutions for API development and manufacturing services.

    Contact Supplier Contact Supplier
    Flag Israel
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2012-11-23

    Pay. Date : 2012-11-13

    DMF Number : 22160

    Submission : 2008-10-31

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF BR, CA, ... arrow-down
    ✖
    Available Reg Filing : BR, CA, ASMF
    AUDIT
    TAPI Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Hubei Honch Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AES 2024
    Not Confirmed
    arrow

    Hubei Honch Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 39499

    Submission : 2024-06-15

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 62158-0011

    Start Marketing Date : 2021-12-01

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Hainan Shuangcheng Pharmaceuticals

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AES 2024
    Not Confirmed
    arrow

    Hainan Shuangcheng Pharmaceuticals

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2022-02-17

    Pay. Date : 2022-01-18

    DMF Number : 36559

    Submission : 2022-01-17

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Suppliers

    read-more
    read-more

    01

    Biophore India Pharmaceuticals Pvt ...

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bortezomib

    About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...

    Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-approved API manufacturing facilities, a dedicated intermediate facility, and a R&D laboratory housing 400 scientists, Biophore has positioned itself as a global leader among API companies. It consistently ranks among the top 10 US DMF filers and has obtained over 150 patents worldwide in process and polymorph areas. Biophore's facilities have an impressive track record of successful audits by regulatory bodies such as USFDA, EMEA, ANVISA, COFEPRIS, and WHO GMP.
    Biophore

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    LGM Pharma

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bortezomib

    About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

    LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    DKSH

    Switzerland
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

    Contact Supplier Contact Supplier
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bortezomib

    About the Company : DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering g...

    DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering growth for businesses in Asia and beyond for over 155 years. DKSH operates in 36 markets, is listed on the SIX Swiss Exchange, employs 33,100 specialists, and generated net sales of CHF 11.1 billion in 2021. It is the leading global distributor of innovative pharma ingredients for pharmaceutical synthesis and formulation. It offers a range of products, ranging from animal care products to packaging materials, intermediates to nutraceuticals, and APIs to excipients.
    DKSH Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Dr. Reddy's Laboratories

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bortezomib

    About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

    Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale
    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Gonane Pharma

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothGonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bortezomib

    About the Company : Gonane Pharma, is a contract pharmaceutical company located in Gujarat, India, specializing in the manufacturing and marketing of Corticosteroids, Hormones, Antivirals, and Oncolog...

    Gonane Pharma, is a contract pharmaceutical company located in Gujarat, India, specializing in the manufacturing and marketing of Corticosteroids, Hormones, Antivirals, and Oncology products. The company's core strength lies in its dedicated team, and its promoters bring over 25 years of experience in manufacturing, promoting products, and managing audits for regulated markets such as the EU, Mexico, China, Korea, and Russia. GONANE PHARMA is actively engaged in discussions with Japanese customers and anticipates further expansion into additional markets.
    Gonane Pharma

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    HRV Global Life Sciences

    India
    arrow
    CPHI Middle east
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothHRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bortezomib

    About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...

    HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It offers services such as sourcing, manufacturing & supply, helping partners enter new markets worldwide. Its strong partnerships with major players in the pharma and food additive industries help HRV Global effectively promote projects and products. HRV Global represents over 30 large Indian drugmakers, primarily targeting Europe, the US & the Middle East markets. Headquartered in India, HRV Global has offices in the US, Switzerland, Dubai, Lithuania & Turkey.
    HRV Global Life Sciences

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Tofigh Daru

    Iran
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTofigh Daru develops & synthesizes a diverse range of APIs in Anticancer, Narcotics, Cardiovascular to Immunomodulatory Segments.

    Contact Supplier Contact Supplier
    Flag Iran
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bortezomib

    About the Company : Tofigh Daru (TODACO) belongs to the Tamin Pharmaceutical Investment Company, the biggest pharmaceutical holding in Iran. TODACO develops novel APIs in therapeutic categories like A...

    Tofigh Daru (TODACO) belongs to the Tamin Pharmaceutical Investment Company, the biggest pharmaceutical holding in Iran. TODACO develops novel APIs in therapeutic categories like Anti-cancer, Anti-diabetics, Cardiovascular & Narcotics. Today, we boast to be the one & only producer of specialized APIs like Glatiramer, Fentanyl, Remifentanil, Atracurium, and peptides including long-acting Triptorelin and we have 5 PIC/s GMP-approved production lines. We also produce semi-finished products, granules for hazardous substances & FDF know-how, tech transfers & CTD compilations. We are exporting our products to Turkey, Bulgaria, Russia, & Algeria.
    Tofigh Daru

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    TAPI Technology & API Services

    Israel
    arrow
    CPhI WW Frankfurt
    Booth #6.1A32
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTAPI offers customized CDMO Solutions for API development and manufacturing services.

    Contact Supplier Contact Supplier
    Flag Israel
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bortezomib

    About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...

    Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, driving progress in the pharmaceutical industry. Leveraging our extensive experience and world-class expertise, we deliver one of the most comprehensive API portfolios in the industry. Additionally, we provide tailored CDMO services, harnessing our proficiency in diverse technologies to meet our partners' unique needs, ensuring flexibility and excellence in every project.
    TAPI Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Aspen Biopharma Labs

    India
    AES 2024
    Not Confirmed
    arrow

    Aspen Biopharma Labs

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bortezomib

    About the Company : Aspen Biopharma Labs is a multifaceted company that was established in 2014. Aspen Bio Pharma defines development and novelty as a challenge for competitive markets to provide impr...

    Aspen Biopharma Labs is a multifaceted company that was established in 2014. Aspen Bio Pharma defines development and novelty as a challenge for competitive markets to provide improved health services to people, through pioneering Research & Development in agreement with the latest principles to ensure safe and secured wellness. The Company is established in bringing the benefit of high quality APIs & Finished Formulations, yet reasonably priced, to patients in India and other emerging markets.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Jiwan Pharmaceutical Technology Co....

    China
    AES 2024
    Not Confirmed
    arrow

    Jiwan Pharmaceutical Technology Co....

    China
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Bortezomib

    About the Company : Located in beautiful Spring City-Jinan,Jiwan is a high-tech pharmaceutical company,specializing in R&D, technology transfer and technical consulting of biotechnology and pharmaceut...

    Located in beautiful Spring City-Jinan,Jiwan is a high-tech pharmaceutical company,specializing in R&D, technology transfer and technical consulting of biotechnology and pharmaceutical technology. Moreover, Jiwan has the right of dealing import and export business of APIs,intermediates and fine chemical goods. Jiwan has a group of high-level specialists from various fields of pharmaceutics and its related sciences who have rich experence and professional research talents and have been working together for more than 10 years.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"BORTEZOMIB","year":"2021","qtr":"Q1","strtotime":1616956200,"product":"BORTEZOMIB IHS","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"ERIOCHEM S.A.","customerCountry":"ARGENTINA","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"3615.4","totalValueFC":"3578.1","currency":"USD","unitRateINR":260490.59,"date":"29-Mar-2021","totalValueINR":"260490.59","totalValueInUsd":"3578.1","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"9738326","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"BORTEZOMIB","year":"2021","qtr":"Q2","strtotime":1617215400,"product":"BORTEZOMIB IHS(QTY:40 GMS)","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES BA","customer":"LABORATORIO KEMEX S.A.","customerCountry":"ARGENTINA","quantity":"0.04","actualQuantity":"40","unit":"GMS","unitRateFc":"920.2","totalValueFC":"35622.5","currency":"USD","unitRateINR":66301.600000000006,"date":"01-Apr-2021","totalValueINR":"2652064","totalValueInUsd":"35622.5","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"9835259","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"BORTEZOMIB","year":"2021","qtr":"Q2","strtotime":1621362600,"product":"BORTEZOMIB IHS (QTY: 20 GMS)","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"BIO SIDUS S A","customerCountry":"ARGENTINA","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"1060","totalValueFC":"20164","currency":"USD","unitRateINR":73850,"date":"19-May-2021","totalValueINR":"1477000","totalValueInUsd":"20164","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"1862887","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1624818600,"product":"BORTEZOMIB IHS(QTY:40 GMS)","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES BA","customer":"LABORATORIOS RICHMOND S.A.C.I.F","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.04","actualQuantity":"40","unit":"GMS","unitRateFc":"946.9","totalValueFC":"37106","currency":"USD","unitRateINR":68224.625,"date":"28-Jun-2021","totalValueINR":"2728985","totalValueInUsd":"37106","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"2727752","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1624991400,"product":"BORTEZOMIB(QTY:100 GMS)","address":"2ND FLOOR, SERENE CHAMBERS,ROAD NO. 7, BANJARA HILLS,","city":"HYDEABAD.AP","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"MONTREAL-DORAVAL APT","customer":"PHARMASCIENCE INC.","customerCountry":"CANADA","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"1496.8","totalValueFC":"146636.1","currency":"USD","unitRateINR":107844.481,"date":"30-Jun-2021","totalValueINR":"10784448.1","totalValueInUsd":"146636.1","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"2798734","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"2ND FLOOR, SERENE CHAMBERS,ROAD NO. 7, BANJARA HILLS,, HYDEABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1625682600,"product":"BORTEZOMIB(QTY:2 GMS)","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"CATALENT PHARMA SOLUTIONS","customerCountry":"CANADA","quantity":"0.00","actualQuantity":"2","unit":"GMS","unitRateFc":"3575.3","totalValueFC":"6913","currency":"USD","unitRateINR":257600,"date":"08-Jul-2021","totalValueINR":"515200","totalValueInUsd":"6913","indian_port":"HYDERABAD AIR","hs_no":"29329990","bill_no":"2983626","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1626892200,"product":"BORTEZOMIB IHS(QTY:20 GMS)","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES BA","customer":"LABORATORIOS IMA S.A.I.C","customerCountry":"ARGENTINA","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"981.2","totalValueFC":"18972.7","currency":"USD","unitRateINR":70698.600000000006,"date":"22-Jul-2021","totalValueINR":"1413972","totalValueInUsd":"18972.7","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"3296984","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1633890600,"product":"BORTEZOMIB IHS","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"BORYUNG PHARMACEUTICAL CO., LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.03","actualQuantity":"0.026","unit":"KGS","unitRateFc":"2000000","totalValueFC":"51166.7","currency":"USD","unitRateINR":147423076.92307693,"date":"11-Oct-2021","totalValueINR":"3833000","totalValueInUsd":"51166.7","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"5220753","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1633890600,"product":"BORTEZOMIB IHS","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"BORYUNG PHARMACEUTICAL CO., LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.04","actualQuantity":"0.038","unit":"KGS","unitRateFc":"1900000","totalValueFC":"71110.1","currency":"USD","unitRateINR":140184210.52631578,"date":"11-Oct-2021","totalValueINR":"5327000","totalValueInUsd":"71110.1","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"5224552","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1634063400,"product":"BORTEZOMIB IHS","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"HO CHI MINH C","customer":"HERA BIOPHARMACEUTICAL CO.LTD","customerCountry":"VIETNAM","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"950000","totalValueFC":"9117.4","currency":"USD","unitRateINR":68300000,"date":"13-Oct-2021","totalValueINR":"683000","totalValueInUsd":"9117.4","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"5283245","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"VIETNAM, DEMOCRATIC REP. OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1634063400,"product":"BORTEZOMIB IHS","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"TUNIS","customer":"NEAPOLIS PHARMA","customerCountry":"TUNISIA","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"1950000","totalValueFC":"18835.4","currency":"USD","unitRateINR":141100000,"date":"13-Oct-2021","totalValueINR":"1411000","totalValueInUsd":"18835.4","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"5283201","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TUNISIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1641580200,"product":"BORTEZOMIB WS","address":"PLOT NO 175, 5-12-181\/8\/D,MANGAPURA MOULAALI, HYDERABAD, Medchal - Malk","city":"HYDERABAD","supplier":"DR.JCR BIO SCIENCES ","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"VEMILAC SAN. VE TIC. A.S.","customerCountry":"TURKEY","quantity":"0.00","actualQuantity":"0.4","unit":"GMS","unitRateFc":"400","totalValueFC":"161.1","currency":"USD","unitRateINR":30000,"date":"08-Jan-2022","totalValueINR":"12000","totalValueInUsd":"161.1","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"7339521","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO 175, 5-12-181\/8\/D,MANGAPURA MOULAALI, HYDERABAD, Medchal - Malk, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1644431400,"product":"BORTEZOMIB WS","address":"12 6 214 A1, YERMARUS CAMP CROSS,H YDERABAD ROAD","city":"RAICHUR,KARNATAKA","supplier":"SHILPA MEDICARE","supplierCountry":"INDIA","foreign_port":"CHENGDU","customer":"KINDOS PHARMACEUTICALS CO.","customerCountry":"CHINA","quantity":"0.00","actualQuantity":"0.4","unit":"GMS","unitRateFc":"10000","totalValueFC":"3708.8","currency":"USD","unitRateINR":695000,"date":"10-Feb-2022","totalValueINR":"278000","totalValueInUsd":"3708.8","indian_port":"HYDERABAD AIR","hs_no":"29419019","bill_no":"8119128","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"12 6 214 A1, YERMARUS CAMP CROSS,H YDERABAD ROAD, RAICHUR,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1644777000,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"HIKMA PHARMACEUTICALS","customerCountry":"EGYPT","quantity":"0.04","actualQuantity":"0.04","unit":"KGS","unitRateFc":"2000000","totalValueFC":"78191.6","currency":"USD","unitRateINR":146525000,"date":"14-Feb-2022","totalValueINR":"5861000","totalValueInUsd":"78191.6","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"8200559","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1645036200,"product":"BORTEZOMIB IHS (QTY: 20 GMS)","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"LABORATORIO KEMEX S.A.","customerCountry":"ARGENTINA","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"1100","totalValueFC":"20465.1","currency":"USD","unitRateINR":76700,"date":"17-Feb-2022","totalValueINR":"1534000","totalValueInUsd":"20465.1","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"8288677","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1646850600,"product":"BORTEZOMIB","address":"12 6 214 A1, YERMARUS CAMP CROSS,H YDERABAD ROAD","city":"RAICHUR,KARNATAKA","supplier":"SHILPA MEDICARE","supplierCountry":"INDIA","foreign_port":"HAMBURG - FUHLSBUETT","customer":"STADAPHARM HANN.","customerCountry":"GERMANY","quantity":"0.01","actualQuantity":"0.009","unit":"KGS","unitRateFc":"1300000","totalValueFC":"12267.2","currency":"EUR","unitRateINR":103888888.8888889,"date":"10-Mar-2022","totalValueINR":"935000","totalValueInUsd":"12267.2","indian_port":"HYDERABAD AIR","hs_no":"29419019","bill_no":"8833931","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"12 6 214 A1, YERMARUS CAMP CROSS,H YDERABAD ROAD, RAICHUR,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1647196200,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"BLAU FARMACEUTICA","customerCountry":"BRAZIL","quantity":"0.02","actualQuantity":"0.02","unit":"KGS","unitRateFc":"1550000","totalValueFC":"29966.1","currency":"USD","unitRateINR":114200000,"date":"14-Mar-2022","totalValueINR":"2284000","totalValueInUsd":"29966.1","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"8930985","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1647801000,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"M\/S. BORYUNG PHARMA., LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.03","actualQuantity":"0.027","unit":"KGS","unitRateFc":"1900000","totalValueFC":"50289","currency":"USD","unitRateINR":141962962.96296296,"date":"21-Mar-2022","totalValueINR":"3833000","totalValueInUsd":"50289","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"9090502","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648146600,"product":"BORTEZOMIB","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"THYMOORGAN PHAMAZIE GMBH","customerCountry":"GERMANY","quantity":"1.21","actualQuantity":"1208","unit":"GMS","unitRateFc":"1350","totalValueFC":"1608984.3","currency":"USD","unitRateINR":101519.86754966888,"date":"25-Mar-2022","totalValueINR":"122636000","totalValueInUsd":"1608984.3","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"9215774","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648405800,"product":"BORTEZOMIB(QTY:242 GMS)","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"GLENMARK PHARMACEUTICALS","customerCountry":"ARGENTINA","quantity":"0.24","actualQuantity":"242","unit":"GMS","unitRateFc":"2000","totalValueFC":"475206.4","currency":"USD","unitRateINR":149669.42148760331,"date":"28-Mar-2022","totalValueINR":"36220000","totalValueInUsd":"475206.4","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"9277338","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652034600,"product":"BORTEZOMIB IHS (QTY:0.035 KGS)","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"TUNIS","customer":"TO THE ORDER OF","customerCountry":"TUNISIA","quantity":"0.04","actualQuantity":"0.035","unit":"KGS","unitRateFc":"1550000","totalValueFC":"51859.5","currency":"USD","unitRateINR":114514285.7142857,"date":"09-May-2022","totalValueINR":"4008000","totalValueInUsd":"51859.5","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"1270825","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TUNISIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652898600,"product":"BORTEZOMIB IHS(QTY:40 GMS)","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF","customerCountry":"ARGENTINA","quantity":"0.04","actualQuantity":"40","unit":"GMS","unitRateFc":"1030","totalValueFC":"40162.7","currency":"USD","unitRateINR":77600,"date":"19-May-2022","totalValueINR":"3104000","totalValueInUsd":"40162.7","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"1504019","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657132200,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"RIGA","customer":"TO THE ORDER OF","customerCountry":"LATVIA","quantity":"0.05","actualQuantity":"50","unit":"GMS","unitRateFc":"1300","totalValueFC":"63144.1","currency":"USD","unitRateINR":100420,"date":"07-Jul-2022","totalValueINR":"5021000","totalValueInUsd":"63144.1","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"2666110","productDescription":"API","marketType":"REGULATED MARKET","country":"LATVIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1658514600,"product":"BORTEZOMIB","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"MONTREAL-DORAVAL APT","customer":"PHARMASCIENCE INC","customerCountry":"CANADA","quantity":"0.10","actualQuantity":"102","unit":"GMS","unitRateFc":"1200","totalValueFC":"121157.2","currency":"USD","unitRateINR":94450.980392156867,"date":"23-Jul-2022","totalValueINR":"9634000","totalValueInUsd":"121157.2","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"3012794","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1660674600,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF","customerCountry":"ARGENTINA","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"1250000","totalValueFC":"11474.6","currency":"USD","unitRateINR":91300000,"date":"17-Aug-2022","totalValueINR":"913000","totalValueInUsd":"11474.6","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"3550914","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1660761000,"product":"BORTEZOMIB","address":"","city":"","supplier":"SHILPA PHARMA LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"CHENGDU","customer":"KINDOS PHARMACEUTICALS CO.","customerCountry":"CHINA","quantity":"0.22","actualQuantity":"0.224","unit":"KGS","unitRateFc":"500000","totalValueFC":"110296.8","currency":"USD","unitRateINR":39178571.428571425,"date":"18-Aug-2022","totalValueINR":"8776000","totalValueInUsd":"110296.8","indian_port":"HYDERABAD AIR","hs_no":"29419019","bill_no":"3578856","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1667413800,"product":"BORTEZOMIB PHARMA BATCH NO.BORT322001 MF","address":"318 3RD FLOOR, U S COMPLEX MUTHURA ROAD, JASOLA","city":"NEW DELHI","supplier":"XENONE HEALTHCARE PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"ALMATY","customer":"PFK ELEAS LLP","customerCountry":"KAZAKHSTAN","quantity":"0.01","actualQuantity":"0.005","unit":"KGS","unitRateFc":"1150000","totalValueFC":"5575.1","currency":"USD","unitRateINR":91000000,"date":"03-Nov-2022","totalValueINR":"455000","totalValueInUsd":"5575.1","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"5227126","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"KAZAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"318 3RD FLOOR, U S COMPLEX MUTHURA ROAD, JASOLA, NEW DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670956200,"product":"BORTEZOMIB","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"HIKMA PHARMACEUTICALS","customerCountry":"GERMANY","quantity":"1.19","actualQuantity":"1192","unit":"GMS","unitRateFc":"1000","totalValueFC":"1161537.9","currency":"USD","unitRateINR":80300.335570469804,"date":"14-Dec-2022","totalValueINR":"95718000","totalValueInUsd":"1161537.9","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"6144363","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1671474600,"product":"BORTEZOMIB BATCH NO. 8920NCE002 MFG. DT.","address":"B-310, SOM DATT CHAMBERS, 1,,BHIKA JI CAMA PLACE,","city":"NEW DELHI,DELHI","supplier":"FRESENIUS SE & CO. KGAA","supplierCountry":"INDIA","foreign_port":"BUCHAREST","customer":"ROMPHARM COMPANY S.R.L.","customerCountry":"ROMANIA","quantity":"0.02","actualQuantity":"15","unit":"GMS","unitRateFc":"650","totalValueFC":"9975","currency":"EUR","unitRateINR":54800,"date":"20-Dec-2022","totalValueINR":"822000","totalValueInUsd":"9975","indian_port":"DELHI AIR","hs_no":"29242960","bill_no":"6289067","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ROMANIA","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"B-310, SOM DATT CHAMBERS, 1,,BHIKA JI CAMA PLACE,, NEW DELHI,DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1673461800,"product":"BORTEZOMIB RS(QTY:1500 MGS)","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"MONTREAL-DORAVAL APT","customer":"PHARMASCIENCE INC.","customerCountry":"CANADA","quantity":"0.00","actualQuantity":"1.5","unit":"GMS","unitRateFc":"5000","totalValueFC":"7277.4","currency":"USD","unitRateINR":396666.66666666669,"date":"12-Jan-2023","totalValueINR":"595000","totalValueInUsd":"7277.4","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"6910141","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1676485800,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER","customerCountry":"ARGENTINA","quantity":"0.02","actualQuantity":"0.022","unit":"KGS","unitRateFc":"850000","totalValueFC":"18065.1","currency":"USD","unitRateINR":67818181.818181828,"date":"16-Feb-2023","totalValueINR":"1492000","totalValueInUsd":"18065.1","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"7830597","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677090600,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"RIGA","customer":"TO THE ORDER","customerCountry":"LATVIA","quantity":"0.04","actualQuantity":"43","unit":"GMS","unitRateFc":"1300","totalValueFC":"55151.9","currency":"USD","unitRateINR":105930.23255813954,"date":"23-Feb-2023","totalValueINR":"4555000","totalValueInUsd":"55151.9","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"8006678","productDescription":"API","marketType":"REGULATED MARKET","country":"LATVIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677090600,"product":"BORTEZOMIB RR ISOMER (QTY:200 MGS)","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"HAMBURG - FUHLSBUETT","customer":"MEDAC","customerCountry":"GERMANY","quantity":"0.00","actualQuantity":"0.2","unit":"GMS","unitRateFc":"5700","totalValueFC":"1126","currency":"USD","unitRateINR":465000,"date":"23-Feb-2023","totalValueINR":"93000","totalValueInUsd":"1126","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"7996711","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677090600,"product":"BORTEZOMIB RS ISOMER (QTY:200 MGS)","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"HAMBURG - FUHLSBUETT","customer":"MEDAC","customerCountry":"GERMANY","quantity":"0.00","actualQuantity":"0.2","unit":"GMS","unitRateFc":"5700","totalValueFC":"1126","currency":"USD","unitRateINR":465000,"date":"23-Feb-2023","totalValueINR":"93000","totalValueInUsd":"1126","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"7996711","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677090600,"product":"BORTEZOMIB SS ISOMER (QTY:150 MGS)","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"HAMBURG - FUHLSBUETT","customer":"MEDAC","customerCountry":"GERMANY","quantity":"0.00","actualQuantity":"0.15","unit":"GMS","unitRateFc":"5700","totalValueFC":"847.6","currency":"USD","unitRateINR":466666.66666666669,"date":"23-Feb-2023","totalValueINR":"70000","totalValueInUsd":"847.6","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"7996711","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677177000,"product":"BORTEZOMIB RR ISOMER(QTY:100 MGS)","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"LEIPZIG\/HALLE","customer":"HIKMA PHARMACEUTICALS","customerCountry":"GERMANY","quantity":"0.00","actualQuantity":"0.1","unit":"GMS","unitRateFc":"5700","totalValueFC":"569.1","currency":"USD","unitRateINR":470000,"date":"24-Feb-2023","totalValueINR":"47000","totalValueInUsd":"569.1","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"8034581","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677177000,"product":"BORTEZOMIB RS ISOMER(QTY:100 MGS)","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"LEIPZIG\/HALLE","customer":"HIKMA PHARMACEUTICALS","customerCountry":"GERMANY","quantity":"0.00","actualQuantity":"0.1","unit":"GMS","unitRateFc":"5700","totalValueFC":"569.1","currency":"USD","unitRateINR":470000,"date":"24-Feb-2023","totalValueINR":"47000","totalValueInUsd":"569.1","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"8034581","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1679509800,"product":"BORTEZOMIB","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"HIKMA PHARMACEUTICALS","customerCountry":"GERMANY","quantity":"1.24","actualQuantity":"1243","unit":"GMS","unitRateFc":"1000","totalValueFC":"1238462.5","currency":"USD","unitRateINR":81950.12067578439,"date":"23-Mar-2023","totalValueINR":"101864000","totalValueInUsd":"1238462.5","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"8692926","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1681151400,"product":"BORTEZOMIB L-PHENYLALANYL ANALOG(PHARMA","address":"SURVEY NO.542\/2, IKP KNOWLEDGE PAR K,KOLTUR VILLAGE, SHAMIRPET MANDAL","city":"MEDCHAL MALKAJGIRI DISTRICT,TELANGA","supplier":"DAICEL CHIRAL TECHNOLOGIES (INDIA) PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"NEW YORK - JOHN F. K","customer":"UNITED STATES PHARMACOPEIAL ","customerCountry":"UNITED STATES","quantity":"0.00","actualQuantity":"0.8","unit":"GMS","unitRateFc":"7130","totalValueFC":"5649.5","currency":"USD","unitRateINR":578750,"date":"11-Apr-2023","totalValueINR":"463000","totalValueInUsd":"5649.5","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"9218146","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"SURVEY NO.542\/2, IKP KNOWLEDGE PAR K,KOLTUR VILLAGE, SHAMIRPET MANDAL, MEDCHAL MALKAJGIRI DISTRICT,TELANGA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1683484200,"product":"BORTEZOMIB IHS QTY 0 038 KGS","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES BA","customer":"TO THE ORDER","customerCountry":"ARGENTINA","quantity":"0.03","actualQuantity":"0.03","unit":"KGS","unitRateFc":"940000","totalValueFC":"35097.9","currency":"USD","unitRateINR":96266666.666666672,"date":"08-May-2023","totalValueINR":"2888000","totalValueInUsd":"35097.9","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1685471400,"product":"BORTEZOMIB IH BATCH NO BT0030523 MFG DT MAR 2023 RETEST DT FEB 2026","address":"VILLAGE KOLHUPANI P.O.CHANDANWARI Contact No: 9198711","city":"DEHRADUN","supplier":"SHIVALIK RASAYAN LIMITED","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"WORLD MEDICINE","customerCountry":"TURKEY","quantity":"0.01","actualQuantity":"10.1","unit":"GMS","unitRateFc":"275","totalValueFC":"2734.4","currency":"USD","unitRateINR":22277.227722772277,"date":"31-May-2023","totalValueINR":"225000","totalValueInUsd":"2734.4","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"VILLAGE KOLHUPANI P.O.CHANDANWARI Contact No: 9198711, DEHRADUN","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1686681000,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO -","customer":"M\/S.","customerCountry":"URUGUAY","quantity":"0.00","actualQuantity":"0.002","unit":"KGS","unitRateFc":"2350000","totalValueFC":"4124.3","currency":"USD","unitRateINR":169499830.5,"date":"14-Jun-2023","totalValueINR":"338999.661","totalValueInUsd":"4124.3","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"URUGAY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1686940200,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"M\/S","customerCountry":"ARGENTINA","quantity":"0.01","actualQuantity":"0.007","unit":"KGS","unitRateFc":"1250000","totalValueFC":"8650","currency":"USD","unitRateINR":101571444,"date":"17-Jun-2023","totalValueINR":"711000.108","totalValueInUsd":"8650","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695234600,"product":"BORTEZOMIB","address":"2ND FLOOR, SERENE CHAMBERS,","city":"","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"MONTREAL-DORAVAL APT","customer":"PHARMASCIENCE INC","customerCountry":"CANADA","quantity":"0.12","actualQuantity":"115","unit":"GMS","unitRateFc":"1200","totalValueFC":"136311.8","currency":"USD","unitRateINR":98391.304347826081,"date":"21-Sep-2023","totalValueINR":"11315000","totalValueInUsd":"136311.8","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"4082933","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"2ND FLOOR, SERENE CHAMBERS,, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695234600,"product":"BORTEZOMIB W\/S","address":"12 6 214 A1 SHILPA HOUSE HYDERABAD ROAD","city":"RAICHUR","supplier":"SHILPA PHARMA LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"CHENGDU","customer":"TO THE ORDER OF","customerCountry":"CHINA","quantity":"0.00","actualQuantity":"0.4","unit":"GMS","unitRateFc":"10000","totalValueFC":"3843","currency":"USD","unitRateINR":797500,"date":"21-Sep-2023","totalValueINR":"319000","totalValueInUsd":"3843","indian_port":"Hyderabad Air","hs_no":"29419019","bill_no":"4074202","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"12 6 214 A1 SHILPA HOUSE HYDERABAD ROAD, RAICHUR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695321000,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"RIGA","customer":"TO THE ORDER OF .","customerCountry":"LATVIA","quantity":"0.07","actualQuantity":"0.069","unit":"KGS","unitRateFc":"1300000","totalValueFC":"88918.9","currency":"USD","unitRateINR":106971014.49275361,"date":"22-Sep-2023","totalValueINR":"7381000","totalValueInUsd":"88918.9","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"4111623","productDescription":"API","marketType":"REGULATED MARKET","country":"LATVIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695666600,"product":"BORTEZOMIB WS(QTY: 0.250 GMS)","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO -","customer":"TO THE ORDER OF,","customerCountry":"URUGUAY","quantity":"0.00","actualQuantity":"0.25","unit":"GMS","unitRateFc":"10800","totalValueFC":"2674.4","currency":"USD","unitRateINR":888000,"date":"26-Sep-2023","totalValueINR":"222000","totalValueInUsd":"2674.4","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"4200590","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"URUGAY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1696012200,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"TO THE ORDER OF.","customerCountry":"ARGENTINA","quantity":"0.02","actualQuantity":"0.02","unit":"KGS","unitRateFc":"930000","totalValueFC":"18431.9","currency":"USD","unitRateINR":76500000,"date":"30-Sep-2023","totalValueINR":"1530000","totalValueInUsd":"18431.9","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"4314297","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1697135400,"product":"BORTEZOMIB PH EUR","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TO THE ORDER OF.","customerCountry":"EGYPT","quantity":"0.08","actualQuantity":"0.075","unit":"KGS","unitRateFc":"1975000","totalValueFC":"146306.7","currency":"USD","unitRateINR":162360000,"date":"13-Oct-2023","totalValueINR":"12177000","totalValueInUsd":"146306.7","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"4604940","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1697740200,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO -","customer":"TO THE ORDER OF","customerCountry":"URUGUAY","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"640000","totalValueFC":"125460.6","currency":"USD","unitRateINR":52210000,"date":"20-Oct-2023","totalValueINR":"10442000","totalValueInUsd":"125460.6","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"4785214","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"URUGAY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708108200,"product":"BORTEZOMIB","address":"2ND FLOOR, SERENE CHAMBERS,","city":"","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"MONTREAL-DORAVAL APT","customer":"PHARMASCIENCE INC.","customerCountry":"CANADA","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"1200","totalValueFC":"118384.2","currency":"USD","unitRateINR":98227.832799999989,"date":"17-Feb-2024","totalValueINR":"9822783.28","totalValueInUsd":"118384.2","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"7615435","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"2ND FLOOR, SERENE CHAMBERS,, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708281000,"product":"BORTEZOMIB WS","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"TUNIS","customer":"N\/A","customerCountry":"TUNISIA","quantity":"0.24","actualQuantity":"240","unit":"GMS","unitRateFc":"5000","totalValueFC":"25716.6","currency":"USD","unitRateINR":8890.8500000000004,"date":"19-Feb-2024","totalValueINR":"2133804","totalValueInUsd":"25716.6","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"7660013","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TUNISIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708713000,"product":"BORTEZOMIB","address":"12 6 214 A1 SHILPA HOUSE HYDERABAD ROAD","city":"RAICHUR","supplier":"SHILPA PHARMA LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"CHENGDU","customer":"KINDOS PHARMACEUTICALS","customerCountry":"CHINA","quantity":"0.28","actualQuantity":"281","unit":"GMS","unitRateFc":"500","totalValueFC":"138965","currency":"USD","unitRateINR":41033.647010676155,"date":"24-Feb-2024","totalValueINR":"11530454.81","totalValueInUsd":"138965","indian_port":"Hyderabad Air","hs_no":"29419019","bill_no":"7806124","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"12 6 214 A1 SHILPA HOUSE HYDERABAD ROAD, RAICHUR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1709317800,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TO THE ORDER OF.","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.03","actualQuantity":"0.03","unit":"KGS","unitRateFc":"1900000","totalValueFC":"56161.7","currency":"USD","unitRateINR":155447607.33333334,"date":"02-Mar-2024","totalValueINR":"4663428.22","totalValueInUsd":"56161.7","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"7997494","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1713551400,"product":"BORTEZOMIB IHS(QTY:40 GMS)","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF,","customerCountry":"ARGENTINA","quantity":"0.04","actualQuantity":"40","unit":"GMS","unitRateFc":"858","totalValueFC":"33988.2","currency":"USD","unitRateINR":70956.600000000006,"date":"20-Apr-2024","totalValueINR":"2838264","totalValueInUsd":"33988.2","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"9266222","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1713983400,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF","customerCountry":"ARGENTINA","quantity":"0.02","actualQuantity":"0.02","unit":"KGS","unitRateFc":"900000","totalValueFC":"17275.1","currency":"USD","unitRateINR":72130000,"date":"25-Apr-2024","totalValueINR":"1442600","totalValueInUsd":"17275.1","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"9409269","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716748200,"product":"BORTEZOMIB HIS","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TO THE ORDER OF .","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.03","actualQuantity":"0.03","unit":"KGS","unitRateFc":"1900000","totalValueFC":"56188","currency":"USD","unitRateINR":156116680.33333334,"date":"27-May-2024","totalValueINR":"4683500.41","totalValueInUsd":"56188","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"1191349","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717007400,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"RIGA","customer":"TO THE ORDER OF, .","customerCountry":"LATVIA","quantity":"0.03","actualQuantity":"0.03","unit":"KGS","unitRateFc":"1200000","totalValueFC":"35218.2","currency":"USD","unitRateINR":97852766.666666672,"date":"30-May-2024","totalValueINR":"2935583","totalValueInUsd":"35218.2","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"1277487","productDescription":"API","marketType":"REGULATED MARKET","country":"LATVIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717698600,"product":"BORTEZOMIB","address":"2ND FLOOR, SERENE CHAMBERS,","city":"N\/A","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"MONTREAL-DORAVAL APT","customer":"PHARMASCIENCE INC.","customerCountry":"CANADA","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"1200","totalValueFC":"118237.6","currency":"USD","unitRateINR":98704.034700000004,"date":"07-Jun-2024","totalValueINR":"9870403.47","totalValueInUsd":"118237.6","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"1500536","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"2ND FLOOR, SERENE CHAMBERS,, N\/A","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1718821800,"product":"BORTEZOMIB IHS","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TO THE ORDER OF .","customerCountry":"EGYPT","quantity":"0.08","actualQuantity":"0.075","unit":"KGS","unitRateFc":"1975000","totalValueFC":"146208.6","currency":"USD","unitRateINR":162738774.40000001,"date":"20-Jun-2024","totalValueINR":"12205408.08","totalValueInUsd":"146208.6","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"1811309","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729881000,"product":"BORTEZOMIB IHS","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"LABORATORIO KEMEX SA","customerCountry":"ARGENTINA","quantity":"0.02","actualQuantity":"0.02","unit":"KGS","unitRateFc":"1290000","totalValueFC":"24793.2","currency":"USD","unitRateINR":104164500,"date":"26-Oct-2024","totalValueINR":"2083290","totalValueInUsd":"24793.2","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"5161924","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1643308200,"product":"BORTEZOMIB (QTY: 45GMS, VALUE: USD 500\/GM)","address":"PLOT NO.2, MAITHRIVIHAR AMEERPET,","city":"HYDERABAD","supplier":"HANSOH PHARMA","supplierCountry":"CHINA","foreign_port":"#N\/A","customer":"EUGIA PHARMA SPECIALITIES ","customerCountry":"INDIA","quantity":"0.05","actualQuantity":"0.045","unit":"KGS","unitRateFc":"500000","totalValueFC":"22743.6","currency":"USD","unitRateINR":"37650000","date":"28-Jan-2022","totalValueINR":"1694250","totalValueInUsd":"22743.6","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"7266478","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"#N\/A","supplierAddress":"","customerAddress":"PLOT NO.2, MAITHRIVIHAR AMEERPET,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1680287400,"product":"BORTEZOMIB API (8.525 GRAM) (BORTEZOMIB) (SAMPLE OF NCV)","address":"B\/2 MAHALAXMI CHAMBERS 22 BHULABHAI DESAI ROAD Contact No:","city":"MUMBAI","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"ARGENTINA","foreign_port":"NA","customer":"GLENMARK PHARMACEUTICALS","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"0.008525","unit":"KGS","unitRateFc":"2000000","totalValueFC":"17902.7","currency":"USD","unitRateINR":"172104896.2","date":"01-Apr-2023","totalValueINR":"1467194.24","totalValueInUsd":"17902.7","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"5335893","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"B\/2 MAHALAXMI CHAMBERS 22 BHULABHAI DESAI ROAD Contact No:"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1723833000,"product":"BORTEZOMIB \/ BATCH NO:3E004GH7 \/ LICNO:SW\/ND\/CT-17\/2024\/000002342 \/ (QTY:30GRAMS)","address":"PLOT NO 113 114, IIND FLOOR,","city":"KUKATPALLY, HYDERABAD. AP.","supplier":"QILU PHARMACEUTICAL","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"RICONPHARMA INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.03","actualQuantity":"30","unit":"GMS","unitRateFc":"350","totalValueFC":"10621.6","currency":"USD","unitRateINR":"29697.5","date":"17-Aug-2024","totalValueINR":"890925","totalValueInUsd":"10621.6","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"5106010","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"317, XINLUO ROAD, HIGH-TECH ZONE,JINAN 250101SDNF CN","customerAddress":"PLOT NO 113 114, IIND FLOOR,"}]
    29-Mar-2021
    26-Oct-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sarclisa Recommended for EU Approval for Newly Diagnosed Multiple Myeloma

    Details:

    Sarclisa (isatuximab) approved as a first anti-CD38 therapy in combination with Bortezomib and Dexamethasone soc treatment for patients with newly diagnosed transplant-ineligible multiple myeloma.


    Lead Product(s): Isatuximab,Bortezomib,Lenalidomide

    Therapeutic Area: Oncology Brand Name: Sarclisa

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 14, 2024

    Sanofi Company Banner

    01

    Sanofi

    France
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Isatuximab,Bortezomib,Lenalidomide

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Sarclisa Recommended for EU Approval for Newly Diagnosed Multiple Myeloma

    Details : Sarclisa (isatuximab) approved as a first anti-CD38 therapy in combination with Bortezomib and Dexamethasone soc treatment for patients with newly diagnosed transplant-ineligible multiple myeloma.

    Brand Name : Sarclisa

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    November 14, 2024

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sanofi Wins US Approval for Multiple Myeloma Drug in Newly Diagnosed Patients

    Details:

    Sarclisa (isatuximab) approved as a first anti-CD38 therapy in combination with Bortezomib and Dexamethasone soc treatment for patients with newly diagnosed transplant-ineligible multiple myeloma.


    Lead Product(s): Isatuximab,Bortezomib,Lenalidomide

    Therapeutic Area: Oncology Brand Name: Sarclisa

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 21, 2024

    Sanofi Company Banner

    02

    Sanofi

    France
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Isatuximab,Bortezomib,Lenalidomide

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Sanofi Wins US Approval for Multiple Myeloma Drug in Newly Diagnosed Patients

    Details : Sarclisa (isatuximab) approved as a first anti-CD38 therapy in combination with Bortezomib and Dexamethasone soc treatment for patients with newly diagnosed transplant-ineligible multiple myeloma.

    Brand Name : Sarclisa

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    September 21, 2024

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sarclisa Treatment Significantly Improves Survival in Multiple Myeloma Patients

    Details:

    Sarclisa (isatuximab) will be the first anti-CD38 therapy in combination with Bortezomib and Dexamethasone soc treatment for patients with newly diagnosed transplant-ineligible multiple myeloma.


    Lead Product(s): Isatuximab,Bortezomib,Lenalidomide

    Therapeutic Area: Oncology Brand Name: Sarclisa

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 08, 2024

    Sanofi Company Banner

    03

    Sanofi

    France
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Isatuximab,Bortezomib,Lenalidomide

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Sarclisa Treatment Significantly Improves Survival in Multiple Myeloma Patients

    Details : Sarclisa (isatuximab) will be the first anti-CD38 therapy in combination with Bortezomib and Dexamethasone soc treatment for patients with newly diagnosed transplant-ineligible multiple myeloma.

    Brand Name : Sarclisa

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    August 08, 2024

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sarclisa Accepted for FDA Priority Review in Newly Diagnosed Multiple Myeloma

    Details:

    Sarclisa (isatuximab) will be the first anti-CD38 therapy in combination with Bortezomib and Dexamethasone soc treatment for patients with newly diagnosed transplant-ineligible multiple myeloma.


    Lead Product(s): Isatuximab,Bortezomib,Lenalidomide

    Therapeutic Area: Oncology Brand Name: Sarclisa

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 27, 2024

    Sanofi Company Banner

    04

    Sanofi

    France
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Isatuximab,Bortezomib,Lenalidomide

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Sarclisa Accepted for FDA Priority Review in Newly Diagnosed Multiple Myeloma

    Details : Sarclisa (isatuximab) will be the first anti-CD38 therapy in combination with Bortezomib and Dexamethasone soc treatment for patients with newly diagnosed transplant-ineligible multiple myeloma.

    Brand Name : Sarclisa

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    May 27, 2024

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sarclisa® (isatuximab) Phase 3 Trial Met Primary Endpoint of Progression Free Survival in Patients with Newly Diagnosed Multiple Myeloma Not Eligible f...

    Details:

    Sarclisa (isatuximab) is a CD38 monoclonal antibody in combination with standard-of-care bortezomib, lenalidomide and dexamethasone is being evaluated in newly diagnosed multiple myeloma not eligible for transplant.


    Lead Product(s): Isatuximab,Lenalidomide,Bortezomib

    Therapeutic Area: Oncology Brand Name: Sarclisa

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 08, 2023

    Sanofi Company Banner

    05

    Sanofi

    France
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Isatuximab,Lenalidomide,Bortezomib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Sarclisa® (isatuximab) Phase 3 Trial Met Primary Endpoint of Progression Free Survival in Patient...

    Details : Sarclisa (isatuximab) is a CD38 monoclonal antibody in combination with standard-of-care bortezomib, lenalidomide and dexamethasone is being evaluated in newly diagnosed multiple myeloma not eligible for transplant.

    Brand Name : Sarclisa

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    December 08, 2023

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

    Details:

    Launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade® (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration, used to treat multiple myeloma and mantle cell lymphoma.


    Lead Product(s): Bortezomib

    Therapeutic Area: Oncology Brand Name: Bortezomib-Generic

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 27, 2022

    Dr Reddy Company Banner

    06

    Dr. Reddy's Laboratories

    India
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Lead Product(s) : Bortezomib

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial...

    Details : Launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade® (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration, used to treat multiple myeloma and mantle cell lymphoma.

    Brand Name : Bortezomib-Generic

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    July 27, 2022

    Dr Reddy Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEver Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances & suspensions.

    EVER Pharma receives EU approval for a liquid ready to use Bortezomib formulation

    Details:

    Bortezomib EVER Pharma is a proteasome inhibitor small molecule drug candidate, which is indicated for the treatment of patients with multiple myeloma and mantle cell lymphoma.


    Lead Product(s): Bortezomib

    Therapeutic Area: Oncology Brand Name: Bortezomib EVER Pharma

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 09, 2022

    Ever Pharma CB

    07

    Ever Pharma

    Austria
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEver Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances & suspensions.

    Lead Product(s) : Bortezomib

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    EVER Pharma receives EU approval for a liquid ready to use Bortezomib formulation

    Details : Bortezomib EVER Pharma is a proteasome inhibitor small molecule drug candidate, which is indicated for the treatment of patients with multiple myeloma and mantle cell lymphoma.

    Brand Name : Bortezomib EVER Pharma

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    February 09, 2022

    Ever Pharma CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    GSK's ADC Blenrep Delivers Survival Win Against J&J's Darzalex

    Details:

    Blenrep (belantamab mafodotin-blmf) is an anti-BCMA ADC. It is being evaluated in combination with pomalidomide, bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.


    Lead Product(s): Belantamab Mafodotin,Bortezomib,Dexamethasone

    Therapeutic Area: Oncology Brand Name: Blenrep

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 14, 2024

    blank

    08

    GSK

    United Kingdom
    arrow
    Antibody Engineering
    Not Confirmed

    GSK

    United Kingdom
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Belantamab Mafodotin,Bortezomib,Dexamethasone

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    GSK's ADC Blenrep Delivers Survival Win Against J&J's Darzalex

    Details : Blenrep (belantamab mafodotin-blmf) is an anti-BCMA ADC. It is being evaluated in combination with pomalidomide, bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

    Brand Name : Blenrep

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    November 14, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    DARZALEX Quadruplet Approved in EU for Newly Diagnosed Myeloma Patients

    Details:

    Darzalex (daratumumab) a CD38 inhibitor, being evaluated in combination with bortezomib, lenalidomide, dexamethasone for the treatment of newly diagnosed multiple myeloma.


    Lead Product(s): Daratumumab,Lenalidomide,Bortezomib

    Therapeutic Area: Oncology Brand Name: Darzalex

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 23, 2024

    blank

    09

    Johnson & Johnson

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Johnson & Johnson

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Daratumumab,Lenalidomide,Bortezomib

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    DARZALEX Quadruplet Approved in EU for Newly Diagnosed Myeloma Patients

    Details : Darzalex (daratumumab) a CD38 inhibitor, being evaluated in combination with bortezomib, lenalidomide, dexamethasone for the treatment of newly diagnosed multiple myeloma.

    Brand Name : Darzalex

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    October 23, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Antengene Announces XPOVIO® Approved in South Korea For Multiple Myeloma

    Details:

    XPOVIO (selinexor) approved for adult patients with multiple myeloma who have received at least one prior therapy, in combination with bortezomib and dexamethasone.


    Lead Product(s): Selinexor,Bortezomib,Dexamethasone

    Therapeutic Area: Oncology Brand Name: Xpovio

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 17, 2024

    blank

    10

    Antengene

    China
    arrow
    Antibody Engineering
    Not Confirmed

    Antengene

    China
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Selinexor,Bortezomib,Dexamethasone

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Antengene Announces XPOVIO® Approved in South Korea For Multiple Myeloma

    Details : XPOVIO (selinexor) approved for adult patients with multiple myeloma who have received at least one prior therapy, in combination with bortezomib and dexamethasone.

    Brand Name : Xpovio

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    October 17, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Sanofi

    France
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Bortezomibum

    Brand Name : Bortezomib Zentiva

    Dosage Form : Dry Sub

    Dosage Strength : 1mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Sanofi

    France
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Bortezomibum

    Brand Name : Bortezomib Zentiva

    Dosage Form : Dry Sub

    Dosage Strength : 3.5mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Dr. Reddy's Laboratories

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    BORTEZOMIB

    Brand Name : BORTEZOMIB

    Dosage Form : INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

    Dosage Strength : 3.5MG/VIAL

    Packaging :

    Approval Date : 2022-07-26

    Application Number : 202963

    Regulatory Info : RX

    Registration Country : USA

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Dr. Reddy's Laboratories

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : DISCN

    Registration Country : USA

    BORTEZOMIB

    Brand Name : BORTEZOMIB

    Dosage Form : POWDER;INTRAVENOUS

    Dosage Strength : 3.5MG/VIAL

    Packaging :

    Approval Date : 2019-10-04

    Application Number : 206927

    Regulatory Info : DISCN

    Registration Country : USA

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Dr. Reddy's Laboratories

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Lead Market Dossiers- Filed

    Registration Country : India

    Bortezomib

    Brand Name :

    Dosage Form : Injection

    Dosage Strength : 3.5MG/VIAL

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Lead Market Dossiers- Filed

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Dr. Reddy's Laboratories

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Lead Market Dossiers- Approved in both US & EU

    Registration Country : India

    Bortezomib

    Brand Name :

    Dosage Form : Injection

    Dosage Strength : 3.5MG/VIAL

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Lead Market Dossiers- Approved in both US & EU

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Polfa Tarchomin

    Poland
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothPolfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Contact Supplier Contact Supplier
    Flag Poland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Dossier Available

    Registration Country : Poland

    Bortezomib

    Brand Name :

    Dosage Form : Powder for Solution for Injection

    Dosage Strength : 3.5MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Dossier Available

    Registration Country : Poland

    Polfa Tarchomin

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    NanoAlvand

    Iran
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

    Contact Supplier Contact Supplier
    Flag Iran
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Iran

    Bortezomib

    Brand Name : Alvocade

    Dosage Form : Vial

    Dosage Strength : 1MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Iran

    NanoAlvand

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    NanoAlvand

    Iran
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

    Contact Supplier Contact Supplier
    Flag Iran
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Iran

    Bortezomib

    Brand Name : Alvocade

    Dosage Form : Vial

    Dosage Strength : 3.5MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Iran

    NanoAlvand

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Supriya Lifescience

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSupriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : India

    Bortezomib

    Brand Name :

    Dosage Form : Lyophilized Powder for Injection

    Dosage Strength : 1MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : India

    Supriya

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    01

    DR REDDYS

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : No

    TE Code : AP

    BORTEZOMIB

    Brand Name : BORTEZOMIB

    Dosage Form : INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

    Dosage Strength : 3.5MG/VIAL

    Approval Date : 2022-07-26

    Application Number : 202963

    RX/OTC/DISCN : RX

    RLD : No

    TE Code : AP

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    DR REDDYS

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : No

    TE Code :

    BORTEZOMIB

    Brand Name : BORTEZOMIB

    Dosage Form : POWDER;INTRAVENOUS

    Dosage Strength : 3.5MG/VIAL

    Approval Date : 2019-10-04

    Application Number : 206927

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    APOTEX

    Canada
    AES 2024
    Not Confirmed
    arrow

    APOTEX

    Canada
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Canada
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : No

    TE Code : AP

    BORTEZOMIB

    Brand Name : BORTEZOMIB

    Dosage Form : INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

    Dosage Strength : 3.5MG/VIAL

    Approval Date : 2022-05-02

    Application Number : 205533

    RX/OTC/DISCN : RX

    RLD : No

    TE Code : AP

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    BAXTER HLTHCARE CORP

    U.S.A
    AES 2024
    Not Confirmed
    arrow

    BAXTER HLTHCARE CORP

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : No

    TE Code : AP

    BORTEZOMIB

    Brand Name : BORTEZOMIB

    Dosage Form : INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

    Dosage Strength : 3.5MG/VIAL

    Approval Date : 2022-05-02

    Application Number : 213823

    RX/OTC/DISCN : RX

    RLD : No

    TE Code : AP

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    FRESENIUS KABI USA

    U.S.A
    AES 2024
    Not Confirmed
    arrow

    FRESENIUS KABI USA

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : No

    TE Code : AP

    BORTEZOMIB

    Brand Name : BORTEZOMIB

    Dosage Form : INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

    Dosage Strength : 3.5MG/VIAL

    Approval Date : 2022-05-02

    Application Number : 209659

    RX/OTC/DISCN : RX

    RLD : No

    TE Code : AP

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    JIANGSU HANSOH PHARM

    China
    AES 2024
    Not Confirmed
    arrow

    JIANGSU HANSOH PHARM

    China
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : No

    TE Code : AP

    BORTEZOMIB

    Brand Name : BORTEZOMIB

    Dosage Form : INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

    Dosage Strength : 3.5MG/VIAL

    Approval Date : 2022-07-26

    Application Number : 215011

    RX/OTC/DISCN : RX

    RLD : No

    TE Code : AP

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    HOSPIRA

    U.S.A
    AES 2024
    Not Confirmed
    arrow

    HOSPIRA

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : Yes

    TE Code :

    BORTEZOMIB

    Brand Name : BORTEZOMIB

    Dosage Form : POWDER;INTRAVENOUS, SUBCUTANEOUS

    Dosage Strength : 2.5MG/VIAL

    Approval Date : 2022-05-02

    Application Number : 209191

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    MEITHEAL

    U.S.A
    AES 2024
    Not Confirmed
    arrow

    MEITHEAL

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : No

    TE Code : AP

    BORTEZOMIB

    Brand Name : BORTEZOMIB

    Dosage Form : INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

    Dosage Strength : 3.5MG/VIAL

    Approval Date : 2022-07-26

    Application Number : 212958

    RX/OTC/DISCN : RX

    RLD : No

    TE Code : AP

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    MSN

    India
    AES 2024
    Not Confirmed
    arrow

    MSN

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : No

    TE Code : AP

    BORTEZOMIB

    Brand Name : BORTEZOMIB

    Dosage Form : INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

    Dosage Strength : 3.5MG/VIAL

    Approval Date : 2022-07-26

    Application Number : 209622

    RX/OTC/DISCN : RX

    RLD : No

    TE Code : AP

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    TEVA PHARMS USA

    Israel
    AES 2024
    Not Confirmed
    arrow

    TEVA PHARMS USA

    Israel
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Israel
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : No

    TE Code :

    BORTEZOMIB

    Brand Name : BORTEZOMIB

    Dosage Form : INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

    Dosage Strength : 3.5MG/VIAL

    Approval Date : 2022-05-02

    Application Number : 205857

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Europe

    read-more
    read-more

    01

    Helvepharm AG

    France
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Bortezomibum

    Brand Name : Bortezomib Zentiva

    Dosage Form : Dry Sub

    Dosage Strength : 1mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Helvepharm AG

    France
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Bortezomibum

    Brand Name : Bortezomib Zentiva

    Dosage Form : Dry Sub

    Dosage Strength : 3.5mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Accord Healthcare Ltd.

    United Kingdom
    Antibody Engineering
    Not Confirmed
    arrow

    Accord Healthcare Ltd.

    United Kingdom
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Sweden

    bortezomib

    Brand Name : bortezomib Accord

    Dosage Form : POWDER FOR SOLUTION FOR INJECTION

    Dosage Strength : 3.5 MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Accord Healthcare AG

    United Kingdom
    Antibody Engineering
    Not Confirmed
    arrow

    Accord Healthcare AG

    United Kingdom
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Bortezomibum

    Brand Name : Bortezomib Accord

    Dosage Form : Dry Sub

    Dosage Strength : 1mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Accord Healthcare AG

    United Kingdom
    Antibody Engineering
    Not Confirmed
    arrow

    Accord Healthcare AG

    United Kingdom
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Bortezomibum

    Brand Name : Bortezomib Accord

    Dosage Form : Dry Sub

    Dosage Strength : 3.5mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Janssen-Cilag International NV

    Italy
    Antibody Engineering
    Not Confirmed
    arrow

    Janssen-Cilag International NV

    Italy
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Sweden

    bortezomib

    Brand Name : VELCADE

    Dosage Form : PULVER TILL INJEKTIONSVÄTSKA, LÖSNING

    Dosage Strength : 1 MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Janssen-Cilag International

    Italy
    Antibody Engineering
    Not Confirmed
    arrow

    Janssen-Cilag International

    Italy
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    Bortezomib

    Brand Name : Velcade

    Dosage Form : Powder for injection fluid, resolution

    Dosage Strength : 3.5 mg

    Packaging : Hood glass

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Janssen-Cilag AG

    Italy
    Antibody Engineering
    Not Confirmed
    arrow

    Janssen-Cilag AG

    Italy
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Bortezomibum

    Brand Name : Velcade

    Dosage Form : Dry Sub

    Dosage Strength : 1mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Sandoz A / S,

    Switzerland
    Antibody Engineering
    Not Confirmed
    arrow

    Sandoz A / S,

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Sweden

    bortezomib

    Brand Name : bortezomib Sandoz

    Dosage Form : POWDER FOR SOLUTION FOR INJECTION

    Dosage Strength : 3.5 MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Sandoz Pharmaceuticals AG

    Switzerland
    Antibody Engineering
    Not Confirmed
    arrow

    Sandoz Pharmaceuticals AG

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Bortezomibum

    Brand Name : Bortezomib Sandoz

    Dosage Form : Dry Sub

    Dosage Strength : 1mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Canada

    read-more
    read-more

    01

    APOTEX INC

    Canada
    Antibody Engineering
    Not Confirmed
    arrow

    APOTEX INC

    Canada
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Canada
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)

    Brand Name : BORTEZOMIB

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 3.5MG/VIAL

    Packaging : 10ML

    Approval Date :

    Application Number : 2456176

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    JANSSEN INC

    U.S.A
    Antibody Engineering
    Not Confirmed
    arrow

    JANSSEN INC

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)

    Brand Name : VELCADE

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 3.5MG/VIAL

    Packaging : 10 ML

    Approval Date :

    Application Number : 2262452

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    MARCAN PHARMACEUTICALS INC

    Canada
    Antibody Engineering
    Not Confirmed
    arrow

    MARCAN PHARMACEUTICALS INC

    Canada
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Canada
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)

    Brand Name : BORTEZOMIB FOR INJECTION

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 3.5MG/VIAL

    Packaging :

    Approval Date :

    Application Number : 2493306

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    PFIZER CANADA ULC

    U.S.A
    Antibody Engineering
    Not Confirmed
    arrow

    PFIZER CANADA ULC

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)

    Brand Name : BORTEZOMIB FOR INJECTION

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 2.5MG/VIAL

    Packaging : 10ML VIAL

    Approval Date :

    Application Number : 2467003

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    PHARMASCIENCE INC

    Canada
    Antibody Engineering
    Not Confirmed
    arrow

    PHARMASCIENCE INC

    Canada
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Canada
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)

    Brand Name : PMS-BORTEZOMIB

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 3.5MG/VIAL

    Packaging :

    Approval Date :

    Application Number : 2466708

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    SANDOZ CANADA INCORPORATED

    Switzerland
    Antibody Engineering
    Not Confirmed
    arrow

    SANDOZ CANADA INCORPORATED

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)

    Brand Name : BORTEZOMIB FOR INJECTION SDZ

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 3.5MG/VIAL

    Packaging :

    Approval Date :

    Application Number : 2503352

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    TARO PHARMACEUTICALS INC

    U.S.A
    Antibody Engineering
    Not Confirmed
    arrow

    TARO PHARMACEUTICALS INC

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)

    Brand Name : TARO-BORTEZOMIB

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 2.5MG/VIAL

    Packaging :

    Approval Date :

    Application Number : 2511932

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    TEVA CANADA LIMITED

    Israel
    Antibody Engineering
    Not Confirmed
    arrow

    TEVA CANADA LIMITED

    Israel
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Israel
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)

    Brand Name : BORTEZOMIB FOR INJECTION

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 3.5MG/VIAL

    Packaging : I.V.:3.5ML/S.C:1.4ML

    Approval Date :

    Application Number : 2423405

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    TEVA CANADA LIMITED

    Israel
    Antibody Engineering
    Not Confirmed
    arrow

    TEVA CANADA LIMITED

    Israel
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Israel
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)

    Brand Name : ACT BORTEZOMIB

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 3.5MG/VIAL

    Packaging :

    Approval Date :

    Application Number : 2438399

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    DR REDDY'S LABORATORIES LTD

    Country
    Antibody Engineering
    Not Confirmed
    arrow

    DR REDDY'S LABORATORIES LTD

    Country
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)

    Brand Name : BORTEZOMIB FOR INJECTION

    Dosage Form : POWDER FOR SOLUTION

    Dosage Strength : 3.5MG/VIAL

    Packaging : SC: 1.4ML (2.5MG/ML) / IV: 3.5ML (1MG/ML)

    Approval Date :

    Application Number : 2452456

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Granulation

    read-more
    read-more

    Topical

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search